TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18281190

Group type: EXPERIMENTAL
Intervention: One session intervention focused on increasing motivation to quit smoking and reducing anxiety sensitivity
Number of subjects: 96

Group type: COMPARATOR
Intervention: Health information control condition
Number of subjects: 96
Study: 16423739

Group type: EXPERIMENTAL
Intervention: Audiovisual presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory-only presentation
Number of subjects: 0
Study: 12601765

Group type: EXPERIMENTAL
Intervention: INFLUSOME-VAC
Number of subjects: 73

Group type: COMPARATOR
Intervention: Commercial subunit vaccine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Commercial split virion vaccine
Number of subjects: 73
Study: 10870147

Group type: EXPERIMENTAL
Intervention: Treadmill test
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bicycle ergometer test
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Upper extremity ergometer test
Number of subjects: 30
Study: 9357387

Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 250 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Debrisoquin 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mephenytoin 100 mg
Number of subjects: 14
Study: 8387346

Group type: COMPARATOR
Intervention: Chemotherapy alone (etoposide, epirubicin, and cis-platinum, days 1-3, every 21 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by rhGM‐CSF (10 micrograms/kg/day s.c., days 4-14)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chemotherapy preceded and followed by rhGM‐CSF (days -17 to -7 for priming, days 4-14 for rescue)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rhGM‐CSF rescue
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by rhGM‐CSF
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chemotherapy preceded and followed by rhGM‐CSF
Number of subjects: 21
Study: 3523796

Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg plus hydrochlorothiazide 12.5 mg (SDX)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg (HCT)
Number of subjects: 50
Study: 31727672

Group type: EXPERIMENTAL
Intervention: Interactive virtual presence technology (remote assistance via smartphones)
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Live technicians (on-site assistance)
Number of subjects: 1476
Study: 30518400

Group type: EXPERIMENTAL
Intervention: Chiropractic care (spinal manipulation) for 4 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Waiting list (control group) for 4 weeks
Number of subjects: 110
Study: 27259669

Group type: EXPERIMENTAL
Intervention: Shared care programme (one annual comprehensive check-up at the outpatient clinic and three quarterly visits at the general practitioners' office)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Shared care programme
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (four quarterly visits at the outpatient clinic, including an annual comprehensive check-up)
Number of subjects: 140
Study: 25713647

Group type: EXPERIMENTAL
Intervention: Low intensity with blood flow restriction (LIBFR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Moderate intensity (MI, 50%-1RM)
Number of subjects: 14
Study: 22535148

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 250
Study: 21226439

Group type: EXPERIMENTAL
Intervention: Mother-voice (MV) group (n = 23) listening to a recording of their mothers' voices during the perioperative period
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n = 23) wearing headphones with no auditory stimulation
Number of subjects: 46
Study: 18665167

Group type: EXPERIMENTAL
Intervention: Irinotecan 180 mg m‐2 and cetuximab 500 mg m‐2 q2w
Number of subjects: 40
Study: 20813681

Group type: EXPERIMENTAL
Intervention: 8 mg Lornoxicam (L8 group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 16 mg Lornoxicam (L16 group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 4 ml saline (NS group)
Number of subjects: 45
Study: 16281728

Group type: EXPERIMENTAL
Intervention: Removable rigid dressing (RRD)
Number of subjects: 50
Study: 11897411

Group type: EXPERIMENTAL
Intervention: Intranasal powder form of glucagon mixed with microcrystalline cellulose at a ratio of 1:69
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spray solutions of glucagon including 1.5% sodium glycocholate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spray solutions of glucagon including 1% sodium caprate
Number of subjects: 0
Study: 9600795

Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Clodronate 2400 mg/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 8027622

Group type: EXPERIMENTAL
Intervention: Adjuvant intraperitoneal 5‐fluorouracil (5‐FU, 500 mg/m2/day) and intravenous leucovorin (60 mg/m2/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2731750

Group type: EXPERIMENTAL
Intervention: sucralfate 1 g qds (n = 24)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: cimetidine 200 mg tds and 400 mg nocte (n = 22)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: sucralfate 1 g bd during maintenance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg nocte during maintenance
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (20 age and sex matched controls)
Number of subjects: 46
Study: 790548

Group type: EXPERIMENTAL
Intervention: Ketoprofen (150 mg daily in 3 doses of 50 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30690446

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) plus 100 mg micronized progesterone (MP)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 0.3 mg CEE daily plus 100 mg MP
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE daily plus 10 mg dydrogesterone (DHG)
Number of subjects: 123
Study: 29505549

Group type: EXPERIMENTAL
Intervention: Intralipid postconditioning (ILPC) - intravenous infusion of 20% intralipid (2 mL/kg) just 10 minutes before aortic cross-unclamping
Number of subjects: 69

Group type: COMPARATOR
Intervention: Normal saline - equivalent volume to ILPC group
Number of subjects: 69
Study: 27075438

Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study: 25012422

Group type: EXPERIMENTAL
Intervention: 0.25mg oral haloperidol daily for 7 days, followed by placebo for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo throughout the trial
Number of subjects: 48
Study: 22724108

Group type: EXPERIMENTAL
Intervention: Nonthermal atmospheric pressure plasma (APP) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonthermal atmospheric pressure plasma (APP) treatment at the highest input voltage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 0
Study: 20460331

Group type: EXPERIMENTAL
Intervention: Referral to community fall prevention services
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard medical and social care
Number of subjects: 204
Study: 17510742

Group type: EXPERIMENTAL
Intervention: Open haemorrhoidectomy
Number of subjects: 686

Group type: COMPARATOR
Intervention: Closed haemorrhoidectomy
Number of subjects: 686
Study: 15777444

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 microg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care (no cervical priming agent)
Number of subjects: 90
Study: 12452759

Group type: EXPERIMENTAL
Intervention: Addition of salmeterol to low-dose fluticasone propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increasing the dose of fluticasone propionate
Number of subjects: 0
Study: 10036846

Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide gel
Number of subjects: 15
Study: 8926595

Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol once daily for three weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2046107

Group type: EXPERIMENTAL
Intervention: Active treatment (antihypertensive drug treatment with chlorthalidone and atenolol)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 4736
Study: 6786204

Group type: EXPERIMENTAL
Intervention: Three different estrogen‐progestin regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen at half the treatment dose
Number of subjects: 0
Study: 30885242

Group type: EXPERIMENTAL
Intervention: NaldebainÂ® (nalbuphine sebacate) intramuscularly 24 Â± 12 h prior to surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl through 48 h postsurgery
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: NaldebainÂ® (nalbuphine sebacate)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl
Number of subjects: 110
Study: 27913279

Group type: EXPERIMENTAL
Intervention: Low abrasivity anti-sensitivity dentifrice (1% alumina and 5% sodium tripolyphosphate)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ultra-low abrasivity non-alumina dentifrice (5% sodium tripolyphosphate)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Higher abrasivity daily-use whitening dentifrice
Number of subjects: 29

Group type: COMPARATOR
Intervention: Water
Number of subjects: 29
Study: 26474657

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 53

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 53
Study: 27129124

Group type: EXPERIMENTAL
Intervention: Enalapril oral solution (1 mg/mL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril oral solution with a high-fat meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference listed drug (RLD) tablet
Number of subjects: 0
Study: 23021694

Group type: EXPERIMENTAL
Intervention: 10 × 10 criteria
Number of subjects: 143

Group type: COMPARATOR
Intervention: 15 × 15 criteria
Number of subjects: 143
Study: 19718777

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artificial neural networks (ANNs) analysis of LRG and IGF‐I data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic (ROC) analysis
Number of subjects: 0
Study: 17043680

Group type: EXPERIMENTAL
Intervention: Oral Delta(9)-tetrahydrocannabinol (THC)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rectal THC-hemisuccinate (THC-HS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 15188105

Group type: EXPERIMENTAL
Intervention: Preoperative rehabilitation advice reinforced by a patient information booklet
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard pathway of care
Number of subjects: 35
Study: 12506472

Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP) 5 mg/body/day (i.v.) plus 5‐FU 300 mg/body/day (cvi) day 1‐5 for 6 weeks, followed by UFT 200 mg (as tegafur) x 2/day for as long as possible
Number of subjects: 190

Group type: COMPARATOR
Intervention: UFT only administered after surgery as long as possible
Number of subjects: 190
Study: 9719743

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg intravenously 90 minutes prior to induction of anaesthesia (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 30
Study: 8573222

Group type: EXPERIMENTAL
Intervention: Pentalong 50 mg tablets (2 tablets per dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aqueous suspension prepared from 25% PETN/lactose trituration
Number of subjects: 24
Study: 2809002

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg body weight over 15 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (20 ml of saline solution over 15 min)
Number of subjects: 8
Study: 365072

Group type: EXPERIMENTAL
Intervention: tranexamic acid, 4 gm per day for ten consecutive days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study: 31305500

Group type: EXPERIMENTAL
Intervention: Simulation-based curriculum
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 30628566

Group type: EXPERIMENTAL
Intervention: Text messages to HWs on malaria case management
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Text messages to HWs on malaria, pneumonia, and diarrhea case management
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control arm (no messages)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 105
Study: 28215900

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 25477272

Group type: EXPERIMENTAL
Intervention: Qualitative study exploring pregnancy intention and planning through semistructured interviews.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of narratives using content analysis and constant comparison method.
Number of subjects: 66
Study: 24075770

Group type: EXPERIMENTAL
Intervention: MGL-3196 (doses of 50 to 200 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MGL-3196 (200 mg per day)
Number of subjects: 0
Study: 22144926

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 120
Study: 21330794

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided (USG) placement
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional landmark method (no USG)
Number of subjects: 28
Study: 17338683

Group type: EXPERIMENTAL
Intervention: 1% polidocanol foam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3% polidocanol foam
Number of subjects: 80
Study: 15034814

Group type: EXPERIMENTAL
Intervention: Microcoblation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microdermabrasion
Number of subjects: 0
Study: 11411818

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 583

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 583
Study: 9474454

Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin eyedrops, BID
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.3% ofloxacin eyedrops, QID
Number of subjects: 50
Study: 7636050

Group type: EXPERIMENTAL
Intervention: SCH 434 QD (10 mg loratadine + 240 mg pseudoephedrine sulfate)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: SCH 434 QD
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874

Group type: COMPARATOR
Intervention: Pseudoephedrine
Number of subjects: 874

Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 874
Study: 2198085

Group type: EXPERIMENTAL
Intervention: Allergen inhalation challenge
Number of subjects: 9

Group type: COMPARATOR
Intervention: Diluent control
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bronchoconstriction induced by methacholine
Number of subjects: 9
Study: 63673

Group type: EXPERIMENTAL
Intervention: Cimetidine (1g/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31037454

Group type: EXPERIMENTAL
Intervention: Slower rate of infusion of etomidate
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard induction dose of etomidate
Number of subjects: 96
Study: 29099333

Group type: EXPERIMENTAL
Intervention: Tezacaftor-Ivacaftor
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Ivacaftor alone
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 25599107

Group type: COMPARATOR
Intervention: Baseline testing with Wechsler Intelligence Scale for Children‐‐Fourth Edition Short Form (WISC‐IV‐SF) and Delis‐Kaplan Executive Function System (D‐KEFS) subtests; Re-assessment 20 ±2 weeks later with shortened test battery including D‐KEFS subtests, Digit Span, Coding and Symbol Search (WISC‐IV), and BRIEF
Number of subjects: 44
Study: 23343320

Group type: EXPERIMENTAL
Intervention: AIM (Adapted Intervention Mapping)
Number of subjects: 10

Group type: COMPARATOR
Intervention: School Health Index (SHI)
Number of subjects: 10
Study: 21862719

Group type: EXPERIMENTAL
Intervention: ECG biomarkers (477 total, 14 identified as predictive of long-term mortality)
Number of subjects: 33144

Group type: EXPERIMENTAL
Intervention: Derivation subset (n=22,096; deaths, 819)
Number of subjects: 33144

Group type: EXPERIMENTAL
Intervention: Validation subset (n=11,048; deaths, 410)
Number of subjects: 33144
Study: 19489489

Group type: EXPERIMENTAL
Intervention: Ziwu Liuzhu group (n=95)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Routine acupuncture group (n=95)
Number of subjects: 190
Study: 17185122

Group type: EXPERIMENTAL
Intervention: CDF + 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CDF + 2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CDF + 3
Number of subjects: 100

Group type: COMPARATOR
Intervention: Positive controls
Number of subjects: 100

Group type: COMPARATOR
Intervention: Negative controls
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SEM observation
Number of subjects: 100
Study: 15505069

Group type: EXPERIMENTAL
Intervention: Subretinal surgery combined with simultaneous transplantation of autologous retinal pigment epithelial (RPE) cells (group 1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Membrane excision alone (group 2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Subretinal surgery with RPE transplantation (group 1)
Number of subjects: 53
Study: 15221294

Group type: EXPERIMENTAL
Intervention: 131I-SPECT/CT imaging
Number of subjects: 71
Study: 11061521

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 9
Study: 9411344

Group type: EXPERIMENTAL
Intervention: Immunomodulant containing lyophilized bacterial extracts
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 8398831

Group type: EXPERIMENTAL
Intervention: Factor IX concentrate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 6
Study: 2939682

Group type: EXPERIMENTAL
Intervention: Non-opioid premedication (midazolam)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Opioid premedication (papaveretum)
Number of subjects: 18
Study: 2801064

Group type: EXPERIMENTAL
Intervention: Combination of low dose heparin (5.000 IU) and dihydroergotamine (0.5 mg) given subcutaneously every twelve hours (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 55
Study: 31858145

Group type: COMPARATOR
Intervention: Approach #1: Assume SFOL = 0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approach #2: Impute SFOL (population median)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approach #3: Impute Hct (population median)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approach #4: Estimate Hct (Hb/MCHC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approach #5: Assume SFOL = 0 and estimate Hct
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approach #6: Predict SFOL (from WBF) and estimate Hct
Number of subjects: 0
Study: 31125095

Group type: EXPERIMENTAL
Intervention: modMBSR
Number of subjects: 21

Group type: COMPARATOR
Intervention: active control
Number of subjects: 21
Study: 27632530

Group type: EXPERIMENTAL
Intervention: Computer-based training program (special nonsense-syllables with background noise), 3 weeks, twice a week for 1 hour
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Follow-up measurement 2-3 months after training
Number of subjects: 46
Study: 26001627

Group type: EXPERIMENTAL
Intervention: Airflow Perturbation Device during resting tidal breathing (RTB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Airflow Perturbation Device during postexercise breathing (PEB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Airflow Perturbation Device during recovery breathing (RB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise performance
Number of subjects: 24
Study: 22682547

Group type: EXPERIMENTAL
Intervention: Urodynamics investigation by cystometrogram, uroflowmetry and electromyogram (UFM/EMG)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pressure/flow/EMG (P/F/EMG) studies
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Urodynamics (general)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Alpha adrenergic blockers
Number of subjects: 56
Study: 21376892

Group type: EXPERIMENTAL
Intervention: Rehearsal flight (search for a target on the ground)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Last-minute reminder about the mandated minimum altitude
Number of subjects: 0
Study: 19724889

Group type: EXPERIMENTAL
Intervention: Glucosamine administration (1.5 g and 3 g/day for 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-athlete controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soccer players
Number of subjects: 0
Study: 17179022

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg oral dose)
Number of subjects: 13
Study: 15573244

Group type: EXPERIMENTAL
Intervention: Preemptive bupivacaine infiltration (Marcaine) before incision and into muscle layer after incision
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 123
Study: 11765110

Group type: EXPERIMENTAL
Intervention: Pharmacists' involvement in health care delivery
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Counseling by pharmacists
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Collaboration with patients' physicians
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Access to patient-specific clinical data
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Obstacles to implementing pharmaceutical care programs
Number of subjects: 13
Study: 9885752

Group type: EXPERIMENTAL
Intervention: Ciloxan
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Siprogut
Number of subjects: 21